Loading…
HealBerry was cited for unlawfully selling unapproved and misbranded compounded semaglutide drugs over the internet. The company's website falsely claimed its compounded semaglutide products were the "same active ingredient as Ozempic and Wegovy," implying equivalence to FDA-approved drugs when compounded products lack FDA approval, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. This misleading marketing resulted in the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FDCA.